ClinicalTrials.gg
TerminatedNCT00170950ACCOMPLISHUpdated Oct 24, 2023Results posted

Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension

A Phase 3 interventional study of Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1 and Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2 in Hypertension, sponsored by Novartis. Terminated at 5 sites in 5 countries. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2023-10-24.

Sponsored by Novartis · Phase 3, Interventional, and Treatment

How we know

Why this study was terminated
The study was terminated early because of significant efficacy results for the primary endpoint in favor of benazepril/amlodipine treatment.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
11,506
Allocation
Randomized
Ages
55 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 228 studies in Hypertension by Novartis — 5 open to participants now, 6 under way, none of them phase 3. Hypertension · Novartis.

Enrollment
Largest of 223
11,506 · median 300
Started
2003
with 10 others
Phase 3
108 of 228
none open now
Registered
12th of 228
by date

Among the 228 studies in Hypertension by Novartis, this one has the largest enrollment of the 223 interventional ones that give a count, is one of 11 that started in 2003, is one of 108 in phase 3, and was the 12th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.

Browse Hypertension studies →

Open to participants now

5 of the 228 studies in Hypertension by Novartis are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.

This study: 55 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 228 studies in Hypertension by Novartis, or all of them as a file.
02

Study summary

A comparison study of two combination drugs, amlodipine/benazepril and benazepril/HCTZ to evaluate the effectiveness of the combination on reducing heart disease and death in a high risk hypertensive population.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • cardiovascular morbidity
  • cardiovascular mortality
  • benazepril
  • amlodipine
  • high risk population
04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 55 years of age.
  • Previously untreated or treated hypertension.
  • For patients >= 60 years, evidence of at least one CV disease or target organ damage, or for patients 55-59 years evidence of at least two CV diseases or target organ damage from two different organ systems as defined in the protocol.

Exclusion criteria

Exclusion Criteria:

  • Allergy to any of the drugs administered in this trial.
  • Current angina pectoris (ie, no anginal event requiring NTG within 1 month prior to Visit 1).
  • Secondary hypertension.
  • hypertension defined as SBP >= 180 mmHg and/or DBP >= 110 mmHg unresponsive to triple-drug regimens of sympatholytics, diuretics and vasodilators.
  • History of symptomatic heart failure ( classes II-IV) or \< 40%.
  • Myocardial infarction, coronary revascularization (CABG or PCI), unstable angina within one month of Visit 1.
  • Stroke or transient ischemic event () within 3 months of Visit 1.
  • Significant obstructive valvular cardiovascular disease or any valvular disease expected to lead to surgery during the course of the study.
  • Evidence of hepatic disease ( or ALT values >= 2 X ).
  • Impaired renal function (serum creatinine >= 2.5 mg/dL (221 µmol/L)).
  • Baseline serum potassium of > 5.2 meq/L not on potassium supplements.
  • History of including leukemia and lymphoma (but not basal cell skin cancer) within the last 5 years.
  • History of auto immune disorders such as Systemic Lupus Erythematosus.
  • Significant non-cardiovascular illness or condition likely to result in death prior to trial completion, e.g., major organ transplant ( \<5 years).
  • Significant cardiovascular disease such as an aortic aneurysm ≥ 6 cm, likely requiring surgical intervention during the course of the study.

Other protocol-defined exclusion criteria applied to the study.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
11,506 participants (actual)

Study arms

  • Experimental
    Benazepril/amlodipine

    Patients were instructed to take one capsule with water in the morning, except on the morning of their next office visit. On office visit days, study medication was taken after completion of the visit evaluations. Following randomization, all patients were treated at Dose Level 1 for 4 weeks, followed by a forced titration to Dose Level 2 for a subsequent 4 week period. Thereafter, patients were titrated as needed to Dose Level 3 to achieve a target blood pressure of \< 140/\< 90 mm Hg. For patients with diabetes or chronic kidney disease, investigators were encouraged to use a target blood pressure of 130/80 mm Hg.

    Drug: Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1 · Drug: Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2 · Drug: Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter

  • Active comparator
    Benazepril/hydrochlorothiazide

    Patients were instructed to take one capsule with water in the morning, except on the morning of their next office visit. On office visit days, study medication was taken after completion of the visit evaluations. Following randomization, all patients were treated at Dose Level 1 for 4 weeks, followed by a forced titration to Dose Level 2 for a subsequent 4 week period. Thereafter, patients were titrated as needed to Dose Level 3 to achieve a target blood pressure of \< 140/\< 90 mm Hg. For patients with diabetes or chronic kidney disease, investigators were encouraged to use a target blood pressure of 130/80 mm Hg.

    Drug: Benazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1 · Drug: Benazepril/hydrochlorothiazide 40/12.5 mg - Dose Level 2 from Month 1 to Month 2 · Drug: Benazepril/hydrochlorothiazide 40/25 mg - Dose Level 3 from Month 2 to Month 3 and thereafter

Interventions

  • DrugBenazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1

    Benazepril hydrochloride (HCl)/amlodipine besylate 10/5 mg capsules for oral administration once daily.

  • DrugBenazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2

    Benazepril hydrochloride (HCl)/amlodipine besylate 20/5 mg capsules for oral administration once daily.

  • DrugBenazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter

    Benazepril hydrochloride (HCl)/amlodipine besylate: 40/10 mg capsules for oral administration once daily. Patients titrated to this dose level had the possibility of subsequent free add-on antihypertensive agents after month 3 based on target blood pressure.

  • DrugBenazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1

    Benazepril hydrochloride (HCl)/hydrochlorothiazide (HCTZ) 20/12.5 mg capsules for oral administration once daily.

  • DrugBenazepril/hydrochlorothiazide 40/12.5 mg - Dose Level 2 from Month 1 to Month 2

    Benazepril hydrochloride (HCl)/hydrochlorothiazide (HCTZ) 40/12.5 mg capsules for oral administration once daily.

  • DrugBenazepril/hydrochlorothiazide 40/25 mg - Dose Level 3 from Month 2 to Month 3 and thereafter

    Benazepril hydrochloride (HCl)/hydrochlorothiazide (HCTZ) 40/25 mg capsules for oral administration once daily. Patients titrated to this dose level had the possibility of subsequent free add-on antihypertensive agents after month 3 based on target blood pressure.

06

What researchers measure

Primary outcomes

  1. Time-to-event Analysis of Percentage of Patients With a Composite Cardiovascular (CV) Morbidity or Mortality Event

    CV morbidity was defined as non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina, resuscitated sudden death, or coronary revascularization procedure. CV mortality was defined as death due to MI, stroke, coronary intervention, congestive heart failure (CHF), sudden cardiac death, or other CV causes.

    Time frame: For each patient, baseline to time of first CV morbidity or mortality event (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])

Secondary outcomes

  1. Time-to-event Analysis of Percentage of Patients With a Composite Cardiovascular (CV) Morbidity Event

    Cardiovascular morbidity was defined as including any of the following events: non-fatal MI, non-fatal stroke, hospitalization for unstable angina, resuscitated sudden death, or coronary revascularization procedure (PCI or CABG).

    Time frame: For each patient, baseline to time of first CV morbidity event (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])]

  2. Time-to-event Analysis of Percentage of Patients With a Cardiovascular (CV) Mortality Event, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke

    CV mortality was defined as death due to sudden cardiac death, fatal MI, fatal stroke, coronary intervention, congestive heart failure (CHF), or other CV causes.

    Time frame: For each patient, baseline to time of first CV mortality event, MI (non-fatal), or stroke (non-fatal) (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])

07

Results

Posted May 17, 2011
Limitations and caveats
Study was stopped early, as recommended by the Data Monitoring Committee, due to positive efficacy results.

Participant flow

Participant flow — Overall Study
MilestoneBenazepril/AmlodipineBenazepril/Hydrochlorothiazide
Started57445762
Completed48594852
Not completed885910
Withdrew: Death236274
Withdrew: Withdrawal by subject496498
Withdrew: Lost to follow-up134115
Withdrew: Missing21
Withdrew: Termination data not recorded1722

Outcome measures

PrimaryTime-to-event Analysis of Percentage of Patients With a Composite Cardiovascular (CV) Morbidity or Mortality Event

CV morbidity was defined as non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina, resuscitated sudden death, or coronary revascularization procedure. CV mortality was defined as death due to MI, stroke, coronary intervention, congestive heart failure (CHF), sudden cardiac death, or other CV causes.

Time frame:
For each patient, baseline to time of first CV morbidity or mortality event (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])
Reported as:
Number · Percentage of Patients with an event
Time-to-event Analysis of Percentage of Patients With a Composite Cardiovascular (CV) Morbidity or Mortality Event
Percentage of Patients with an eventBenazepril/AmlodipineBenazepril/Hydrochlorothiazide
Time-to-event Analysis of Percentage of Patients With a Composite Cardiovascular (CV) Morbidity or Mortality Event9.611.8
SecondaryTime-to-event Analysis of Percentage of Patients With a Composite Cardiovascular (CV) Morbidity Event

Cardiovascular morbidity was defined as including any of the following events: non-fatal MI, non-fatal stroke, hospitalization for unstable angina, resuscitated sudden death, or coronary revascularization procedure (PCI or CABG).

Time frame:
For each patient, baseline to time of first CV morbidity event (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])]
Reported as:
Number · Percentage of Patients with an Event
Time-to-event Analysis of Percentage of Patients With a Composite Cardiovascular (CV) Morbidity Event
Percentage of Patients with an EventBenazepril/AmlodipineBenazepril/Hydrochlorothiazide
Time-to-event Analysis of Percentage of Patients With a Composite Cardiovascular (CV) Morbidity Event8.610.3
SecondaryTime-to-event Analysis of Percentage of Patients With a Cardiovascular (CV) Mortality Event, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke

CV mortality was defined as death due to sudden cardiac death, fatal MI, fatal stroke, coronary intervention, congestive heart failure (CHF), or other CV causes.

Time frame:
For each patient, baseline to time of first CV mortality event, MI (non-fatal), or stroke (non-fatal) (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])
Reported as:
Number · Percentage of Patients with an Event
Time-to-event Analysis of Percentage of Patients With a Cardiovascular (CV) Mortality Event, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke
Percentage of Patients with an EventBenazepril/AmlodipineBenazepril/Hydrochlorothiazide
Time-to-event Analysis of Percentage of Patients With a Cardiovascular (CV) Mortality Event, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke5.06.3

Adverse events

Collected over Double-blind period. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Benazepril / Amlodipine—1,844/5,740 (32.1%)3,077/5,740 (53.6%)
Benazepril / HCTZ—2,026/5,757 (35.2%)2,663/5,757 (46.3%)
Most frequent serious events
Showing 10 of 1,074
Most frequent serious events
EventBenazepril / AmlodipineBenazepril / HCTZ
Angina unstableCardiac disorders113/5740131/5757
Myocardial infarctionCardiac disorders91/5740126/5757
Coronary artery diseaseCardiac disorders112/5740124/5757
Atrial fibrillationCardiac disorders115/5740113/5757
Angina pectorisCardiac disorders85/5740106/5757
PneumoniaInfections and infestations105/574073/5757
Cardiac failure congestiveCardiac disorders99/574086/5757
Cerebrovascular accidentNervous system disorders86/574088/5757
SyncopeNervous system disorders51/574076/5757
Non-cardiac chest painGeneral disorders64/574050/5757
Most frequent other events
Most frequent other events
EventBenazepril / AmlodipineBenazepril / HCTZ
Oedema peripheralGeneral disorders1787/5740768/5757
DizzinessNervous system disorders1175/57401440/5757
CoughRespiratory, thoracic and mediastinal disorders1172/57401217/5757

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Benazepril/AmlodipineBenazepril/HydrochlorothiazideTotal
Mean68.4 ± 6.8668.3 ± 6.8668.4 ± 6.86
Sex: Female, Male
Sex: Female, Male(Participants)Benazepril/AmlodipineBenazepril/HydrochlorothiazideTotal
Female229622464542
Male344835156963
08

Study locations

5 sites
  • Novartis Pharmaceuticals
    East Hanover, New Jersey 07936, United States
  • sites in Denmark
    Denmark, Denmark
  • sites in Finland
    Finland, Finland
  • sites in Norway
    Norway, Norway
  • sites in Sweden
    Sweden, Sweden
09

References and documents

Publications

  • Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ; ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008 Dec 4;359(23):2417-28. doi: 10.1056/NEJMoa0806182. PubMed 19052124 ↗
  • Brook RD, Kaciroti N, Bakris G, Dahlof B, Pitt B, Velazquez E, Weber MA, Jamerson KA. Cardiovascular Benefits of Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade in Patients Achieving Tight Blood Pressure Control and With Resistant Hypertension. Am J Hypertens. 2021 May 22;34(5):531-539. doi: 10.1093/ajh/hpaa192. PubMed 33216879 ↗
  • Weber MA, Jamerson K, Bakris GL, Weir MR, Zappe D, Zhang Y, Dahlof B, Velazquez EJ, Pitt B. Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. Lancet. 2013 Feb 16;381(9866):537-45. doi: 10.1016/S0140-6736(12)61343-9. Epub 2012 Dec 6. PubMed 23219284 ↗
  • Weber MA, Bakris GL, Jamerson K, Weir M, Kjeldsen SE, Devereux RB, Velazquez EJ, Dahlof B, Kelly RY, Hua TA, Hester A, Pitt B; ACCOMPLISH Investigators. Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol. 2010 Jun 29;56(1):77-85. doi: 10.1016/j.jacc.2010.02.046. PubMed 20620720 ↗
  • Bakris GL, Sarafidis PA, Weir MR, Dahlof B, Pitt B, Jamerson K, Velazquez EJ, Staikos-Byrne L, Kelly RY, Shi V, Chiang YT, Weber MA; ACCOMPLISH Trial investigators. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet. 2010 Apr 3;375(9721):1173-81. doi: 10.1016/S0140-6736(09)62100-0. Epub 2010 Feb 18. PubMed 20170948 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2003, a primary completion of Jan 2008 and a completion of May 2008. It does not say whether these dates are actual or estimated.

Results were first posted in May 2011, 3 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2005
First posted
Sep 15, 2005
Start
Oct 2003
Primary completionActual
Jan 2008
CompletionActual
May 2008
Results first posted
May 17, 2011
Last update
Oct 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00170950
Lead sponsor
Novartis
First posted
Sep 15, 2005
Start date
Oct 2003
Primary completion
Jan 2008
Completion
May 2008
Results posted
May 17, 2011
Last update
Oct 24, 2023

Study contacts

Novartis Pharmaceuticals
study chair · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion